Autonomic Nervous System: Introduction

Muscarinic acetylcholine receptors are G-protein-coupled receptors activated by acetylcholine at parasympathetic postganglionic neuroeffector junctions and at a small number of sympathetically innervated tissues (notably sweat glands). Five subtypes — M1 through M5 — have been identified, each encoded by a distinct gene and distinguished by its G-protein coupling partner, tissue distribution, and functional role. The clinical pharmacology of muscarinic drugs is best understood by knowing which subtypes predominate at each clinically relevant target organ.

The five subtypes divide into two functional groups based on G-protein coupling. M1, M3, and M5 couple to Gq, activating phospholipase C, which generates inositol trisphosphate and diacylglycerol, ultimately increasing intracellular calcium and activating protein kinase C. M2 and M4 couple to Gi, inhibiting adenylyl cyclase, reducing cyclic adenosine monophosphate, and in the heart opening potassium channels that slow sinoatrial node firing and conduction through the atrioventricular node.

The clinical consequence of this subtype division is that most available muscarinic antagonists (atropine, scopolamine, glycopyrrolate, oxybutynin) are non-selective — they block all five subtypes. Their organ-level effects therefore reflect the muscarinic subtype predominating at each target: atropine accelerates heart rate (blocking M2 at the sinoatrial node), dries secretions (blocking M3 at salivary and lacrimal glands), dilates pupils (blocking M3 at the iris sphincter), and relaxes bronchial smooth muscle (blocking M3). Selective M3 antagonists such as tiotropium and ipratropium are used in pulmonary disease precisely because M3 mediates bronchoconstriction.

Adrenergic receptors mediate the actions of norepinephrine (released from sympathetic postganglionic nerve terminals) and epinephrine (released from the adrenal medulla into the bloodstream). All adrenergic receptors are G-protein-coupled. They are classified into two major families — alpha and beta — each with clinically important subtypes. The subtype present at a given tissue determines the nature and direction of the sympathetic response at that organ.

Alpha-1 receptors couple to Gq, activating phospholipase C and raising intracellular calcium. They are located predominantly on vascular smooth muscle, the iris dilator muscle, the prostate and urethral sphincter, and the liver. Activation produces vasoconstriction, mydriasis, and increased urethral resistance. Alpha-1 antagonists (prazosin, tamsulosin, terazosin) lower blood pressure and relax the prostate — the dual utility that makes them useful for both hypertension and benign prostatic hyperplasia.

Alpha-2 receptors couple to Gi, inhibiting adenylyl cyclase and reducing cyclic adenosine monophosphate. They are found in two functionally distinct locations: presynaptically on sympathetic nerve terminals (where activation reduces norepinephrine release — a negative feedback autoreceptor mechanism) and postsynaptically in the central nervous system (where activation reduces sympathetic outflow). Clonidine and alpha-methyldopa exploit central alpha-2 receptors to lower blood pressure. Alpha-2 receptors in the pancreas inhibit insulin secretion, and in platelets promote aggregation.

Beta-1 receptors couple to Gs, stimulating adenylyl cyclase and raising cyclic adenosine monophosphate. They predominate in the heart (sinoatrial node, atrioventricular node, ventricular myocardium) and kidney (juxtaglomerular cells). Activation increases heart rate, conduction velocity, and contractility, and stimulates renin release. Beta-1 selective antagonists (metoprolol, atenolol, bisoprolol) are used for hypertension, heart failure, and arrhythmias, with the selectivity advantage of avoiding bronchoconstriction at therapeutic doses.

Beta-2 receptors also couple to Gs but are concentrated in bronchial smooth muscle, vascular smooth muscle of skeletal muscle beds, the uterus, and the liver. Activation causes bronchodilation, vasodilation in skeletal muscle, uterine relaxation, and glycogenolysis. Selective beta-2 agonists (albuterol, salmeterol, formoterol) are the primary bronchodilators in asthma and chronic obstructive pulmonary disease. Beta-3 receptors in adipose tissue mediate lipolysis; mirabegron targets beta-3 receptors in the bladder detrusor for overactive bladder.

Prolonged or repeated exposure to an agonist reduces the receptor's ability to respond — a phenomenon called desensitization. Two distinct processes underlie this reduction. Rapid desensitization (minutes) results from phosphorylation of the receptor by G-protein-coupled receptor kinases, which recruit arrestin proteins that uncouple the receptor from its G-protein. The receptor remains on the cell surface but no longer signals. This process is reversible once the agonist is removed.

Downregulation (hours to days) involves internalization of receptors from the cell surface into endosomes, followed by either recycling back to the membrane or lysosomal degradation. The result is a net reduction in the number of functional receptors available, producing a sustained decrease in drug response. Clinically, this is the mechanism underlying beta-2 agonist tolerance in asthma with overuse of short-acting rescue inhalers — the bronchodilator response diminishes with chronic over-reliance.

The converse process — upregulation — occurs when receptors are chronically blocked by an antagonist. The cell compensates by increasing receptor number and sensitivity. This is why abrupt withdrawal of beta-blockers can trigger rebound tachycardia and hypertension: the now-upregulated beta-1 receptors respond to endogenous catecholamines with exaggerated effect. The clinical rule is that beta-blockers should always be tapered, never stopped abruptly, in patients with coronary artery disease or hypertension.